What is the 13F Pro Quality Score for NAGE?

13F Pro ranks Niagen Bioscience, Inc. (NAGE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NAGE's current score at https://13fpro.ai/company/NAGE (free sign-up required for the full ranking).

Which hedge funds own the most NAGE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NAGE include BlackRock,, SteelPeak Wealth,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NAGE as soon as new 13F filings post.

Where does 13F Pro source NAGE data?

All Niagen Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Niagen Bioscience, Inc. files with the SEC under CIK 1386570. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NAGE in?

Niagen Bioscience, Inc. (NAGE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives NAGE's revenue?

Per Niagen Bioscience, Inc.'s latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Consumer Products ($24.2M, +6% YoY); Ingredients ($5.4M, -29% YoY); Analytical Reference Standards and Services ($0M, N/A). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/NAGE.

What are NAGE's largest expenses?

Niagen Bioscience, Inc.'s latest 10-Q reports these as the largest expense items: Sales and Marketing ($10.1M, +23% YoY); Cost of Sales ($10.5M, -4% YoY); General and Administrative ($7.0M, -4% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is NAGE research updated on 13F Pro?

NAGE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Niagen Bioscience, Inc.(NAGE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1386570 NAGE stock profile & AI dashboard →

13F Pro Quality Score

53.2/100

Rank #1,405 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

83.4/100

Profitability

61.8/100

Balance Sheet

94.0/100

Earnings Quality

53.8/100

Free Cash Flow

40.9/100

Institutional Flow

7.0/100

Revenue Scale

18.9/100

Dilution Risk

25.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NAGE Scores 53/100

exact factor attribution · 2026-09-11

NAGE's composite is driven by revenue growth and capital efficiency, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.7 pts

83th pct

Capital efficiency

+4.4 pts

94th pct

Profitability

+1.8 pts

62th pct

Earnings quality

+0.4 pts

54th pct

Earnings growth

-0.7 pts

37th pct

Shareholder dilution

-1.2 pts

26th pct

Free cash flow

-1.4 pts

41th pct

Institutional flow

-2.1 pts

7th pct

Scale

-4.7 pts

19th pct

Latest change (2026-08-04): 67 → 60 · ↓ Revenue growth 83→69; ↓ Free cash flow 62→44

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NAGE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Niagen Bioscience, Inc. (NAGE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAGE at 53.2/100 on a 32-signal composite quality model, placing it at rank #1,405 of 2,962 stocks — the top half of the AI-ranked universe. NAGE scores in the top quartile across balance sheet strength (94.0), revenue growth (83.4). Areas of concern include institutional flow (7.0) and revenue scale (18.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Niagen Bioscience, Inc. reports quarterly revenue of $29.8M, net income of $963.0K. Top institutional holders of NAGE by reported 13-F value include BlackRock, SteelPeak Wealth, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NAGE trades on the Nasdaq exchange and files with the SEC under CIK 1386570. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Niagen Bioscience, Inc. directly from SEC EDGAR. Niagen Bioscience, Inc.'s 13F Pro composite quality score has ranged between 37 and 67 since 2024, currently 53.2 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.

What's Driving NAGE's Business? Latest 10-Q Breakdown

✓ 20/20 datapoints verified

AI-extracted from Niagen Bioscience, Inc.'s 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue declined 4% YoY to $29.8M as Ingredients segment weakness and divestiture of Analytical Reference Standards business offset Consumer Products growth.

Biggest Revenue Drivers

Consumer Products$24.2M+6% YoY

Tru Niagen e-commerce channel grew ~$2.5M; offset by $2.3M decline in A.S. Watson Group sales; cross-border China sales increased ~$1.0M.

Ingredients$5.4M-29% YoY

Food-grade Niagen sales declined $1.1M due to softer downstream demand; pharmaceutical-grade sales fell $1.0M from reduced partner purchasing.

Biggest Revenue Drivers

Total revenue: $29.8M-4% YoY

Consumer Products$24.2M+6% YoY

Tru Niagen e-commerce channel grew ~$2.5M; offset by $2.3M decline in A.S. Watson Group sales; cross-border China sales increased ~$1.0M.

Ingredients$5.4M-29% YoY

Food-grade Niagen sales declined $1.1M due to softer downstream demand; pharmaceutical-grade sales fell $1.0M from reduced partner purchasing.

Analytical Reference Standards and Services$0MN/A

Business divested February 2026; Q2 2026 reflects only partial-period operations prior to sale.

Corporate and Other$0.2MN/A

Transition services revenue from post-divestiture agreement with buyer.

Largest Expense Items

Sales and Marketing$10.1M+23% YoY

Higher advertising and marketing spend for brand growth and customer acquisition; expansion of marketing organization personnel costs.

Cost of Sales$10.5M-4% YoY

Consumer Products gross margin improved 40 bps from e-commerce mix shift; Ingredients margin declined 720 bps due to unfavorable product mix and pricing concessions.

General and Administrative$7.0M-4% YoY

Lower royalties and professional fees offset by higher share-based compensation.

Research and Development$1.5M-3% YoY

Pharmaceuticals R&D increased 29% from CRO agreement for development programs; Niagen-allocated R&D to Consumer Products and Ingredients remained flat.

Margins: Gross margin declined 50 bps YoY to 64.8% due to unfavorable product mix in Ingredients (higher food-grade, lower pharmaceutical-grade sales) and pricing concessions to support commercial relationships, partially offset by e-commerce channel growth in Consumer Products. Operating margin compressed significantly to 2.4% from 10.2% YoY due to 760 bps increase in sales and marketing expense as percentage of revenue.

Watch Items from the Filing

Ingredients segment revenue declined 29% YoY; Company attributed decline to NMN competition following FDA's September 2025 determination and customer mix shift, creating significant margin pressure.
Two major customers (Customer C at 26.1% and Customer B at ~23.0% of trade receivables as of June 30, 2026) represent 37.2% of total outstanding receivables, creating collection and revenue concentration risk.
Pending litigation: Elysium Health appeals $9.2M attorneys' fees judgment (with post-judgment interest estimated at ~$10.4M through appeal); Federal Circuit oral arguments held July 9, 2026 with no ruling yet.
Two putative class action complaints filed May–June 2026 in California federal courts challenging Tru Niagen advertising claims; consolidated proceeding with amended complaint due August 14, 2026; no accrual recorded as early stage.
Company operates under sole-source NRC supply agreement with W.R. Grace through April 30, 2029 with ~$20.5M minimum purchase obligation through June 30, 2027; Grace holds crystalline NRC patents limiting alternative sourcing.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$29.8M

Net Income

Q2 2026

$963.0K

ROIC

Q2 2026

3.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+29.9% YoY

$129.4MFY 2025

FY22 $72.0MFY23 $83.6MFY24 $99.6MFY25 $129.4M

Net Income

+103.3% YoY

$17.4MFY 2025

FY22 $-16.5MFY23 $-4.9MFY24 $8.6MFY25 $17.4M

Operating Income

+110.7% YoY

$16.3MFY 2025

FY22 $-18.6MFY23 $-5.6MFY24 $7.7MFY25 $16.3M

EPS (Diluted)

+81.8% YoY

$0.20FY 2025

FY22 $-0.24FY23 $-0.07FY24 $0.11FY25 $0.20

Total Assets

+55.8% YoY

$106.4MFY 2025

FY22 $54.1MFY23 $55.0MFY24 $68.3MFY25 $106.4M

Op. Cash Flow

+11.5% YoY

$13.5MFY 2025

FY22 $-15.1MFY23 $7.1MFY24 $12.1MFY25 $13.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$129.4M +29.9%	$99.6M +19.2%	$83.6M +16.0%	$72.0M +6.8%	$67.4M +13.8%	$59.3M
Net Income	$17.4M +103.3%	$8.6M +273.1%	$-4.9M +70.1%	$-16.5M +39.0%	$-27.1M -36.2%	$-19.9M
Operating Income	$16.3M +110.7%	$7.7M +238.0%	$-5.6M +69.9%	$-18.6M +31.2%	$-27.1M -36.4%	$-19.9M
EPS (Diluted)	$0.20 +81.8%	$0.11 +257.1%	$-0.07 +70.8%	$-0.24 +40.0%	$-0.40 -21.2%	$-0.33
Total Assets	$106.4M +55.8%	$68.3M +24.2%	$55.0M +1.7%	$54.1M -6.5%	$57.8M +50.8%	$38.4M
Operating Cash Flow	$13.5M +11.5%	$12.1M +70.1%	$7.1M +147.1%	$-15.1M +37.5%	$-24.2M -128.0%	$-10.6M

Get alerted when NAGE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Niagen Bioscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NAGE

BlackRock, Inc.
$13.3M4,184,659 sh
SteelPeak Wealth, LLC
$11.2M3,500,129 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.8M2,147,018 sh
Tieton Capital Management, LLC
$6.4M2,008,470 sh
Qube Research & Technologies Ltd
$5.2M1,625,016 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.7M1,478,603 sh
UBS Group AG
$4.1M1,283,296 sh
GOLDMAN SACHS GROUP INC
$4.0M1,262,743 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$3.7M1,171,215 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$3.7M1,166,233 sh

Fund	Value	Shares
BlackRock, Inc.	$13.3M	4,184,659
SteelPeak Wealth, LLC	$11.2M	3,500,129
VANGUARD CAPITAL MANAGEMENT LLC	$6.8M	2,147,018
Tieton Capital Management, LLC	$6.4M	2,008,470
Qube Research & Technologies Ltd	$5.2M	1,625,016
GEODE CAPITAL MANAGEMENT, LLC	$4.7M	1,478,603
UBS Group AG	$4.1M	1,283,296
GOLDMAN SACHS GROUP INC	$4.0M	1,262,743
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$3.7M	1,171,215
VANGUARD PORTFOLIO MANAGEMENT LLC	$3.7M	1,166,233

Companies Similar to NAGE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ELMD

Electromed, Inc.

AI score

Similar quality profile · 2 shared holders

GAMCO INVESTORS, INC. ET AL Teton Advisors, LLC

TCMD

TACTILE SYSTEMS TECHNOLOGY INC

AI score

Similar quality profile · 2 shared holders

AVIVA PLC ROYCE & ASSOCIATES LP

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 5 shared holders

Tieton Capital Management, LLC JACOBS LEVY EQUITY MANAGEMENT, INC SteelPeak Wealth, LLC

PLX

Protalix BioTherapeutics, Inc.

AI score

Similar quality profile

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 2 shared holders

AVIVA PLC Voleon Capital Management LP

VCEL

Vericel Corp

AI score

Similar quality profile · 1 shared holders

Voleon Capital Management LP

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile

CDNA

CareDx, Inc.

AI score

Similar quality profile · 3 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Voleon Capital Management LP ROYCE & ASSOCIATES LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NAGE on your watchlist

Track score changes the day Niagen Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NAGE a good stock to buy?

13F Pro's AI-powered analysis of Niagen Bioscience, Inc. (NAGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NAGE are available on the NAGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NAGE is classified as a small company.

Which hedge funds own NAGE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NAGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Niagen Bioscience, Inc.'s investment landscape.